{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.5","upperLimit":"37.7","value":"29.1"},{"groupId":"OG001","lowerLimit":"27.6","upperLimit":"46.6","value":"37.1"},{"groupId":"OG002","lowerLimit":"35.1","upperLimit":"56.1","value":"45.6"},{"groupId":"OG003","lowerLimit":"50.1","upperLimit":"65.3","value":"57.7"},{"groupId":"OG004","lowerLimit":"44.9","upperLimit":"70.9","value":"57.9"},{"groupId":"OG005","lowerLimit":"47.6","upperLimit":"71.7","value":"59.6"}]}],"title":"Central Reader 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"36.9","upperLimit":"64.8","value":"50.8"},{"groupId":"OG001","lowerLimit":"38.9","upperLimit":"64.6","value":"51.8"},{"groupId":"OG002","lowerLimit":"43.7","upperLimit":"71.1","value":"57.4"},{"groupId":"OG003","lowerLimit":"55.3","upperLimit":"74.6","value":"65.0"},{"groupId":"OG004","lowerLimit":"56.8","upperLimit":"86.7","value":"71.7"},{"groupId":"OG005","lowerLimit":"50.6","upperLimit":"74.9","value":"62.7"}]}],"title":"Central Reader 2"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"24.0","upperLimit":"45.0","value":"34.5"},{"groupId":"OG001","lowerLimit":"33.5","upperLimit":"56.7","value":"45.1"},{"groupId":"OG002","lowerLimit":"38.7","upperLimit":"66.2","value":"52.5"},{"groupId":"OG003","lowerLimit":"55.9","upperLimit":"73.9","value":"64.9"},{"groupId":"OG004","lowerLimit":"41.5","upperLimit":"75.9","value":"58.7"},{"groupId":"OG005","lowerLimit":"47.3","upperLimit":"74.2","value":"60.8"}]}],"title":"Central Reader 3"}],"denoms":[{"counts":[{"groupId":"OG000","value":"105"},{"groupId":"OG001","value":"63"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"88"},{"groupId":"OG004","value":"36"},{"groupId":"OG005","value":"31"}],"units":"Participants"}],"description":"Region-Level PPV is defined as the regions which are true positive out of all regions with positive lesions.. The last PSA level before the rhPSMA-7.3 (18F) PET scan was used to stratify patients.","dispersionType":"95% Confidence Interval","groups":[{"description":"PSA \\< 0.5","id":"OG000","title":"PSA <0.5"},{"description":"0.5 ≤ PSA \\< 1.0","id":"OG001","title":"0.5≤PSA<1.0"},{"description":"1.0 ≤ PSA \\< 2.0","id":"OG002","title":"1.0≤PSA<2.0"},{"description":"2.0 ≤ PSA \\< 5.0","id":"OG003","title":"2.0≤PSA<5.0"},{"description":"5.0 ≤ PSA \\< 10.0","id":"OG004","title":"5.0≤PSA<10.0"},{"description":"PSA ≥ 10.0","id":"OG005","title":"PSA≥10.0"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Population (EAP): all patients who received rhPSMA-7.3 (18F) injection followed by a PET/CT scan and for whom sufficient data are available to permit a clear classification following the SoT algorithm.","reportingStatus":"POSTED","timeFrame":"Conventional images within 90 days of rhPSMA7.3 (18F) PET, followed by biopsy within 60 days post-PET scan or confirmatory imaging within 90 days post-PET scan","title":"Region-level PPV of rhPSMA-7.3 (18F) PET Stratified by PSA Level","type":"SECONDARY","unitOfMeasure":"percentage"}